Development and Evaluation of Gastrobioadhesive Glimepiride Sustained Release Matrix Tablet Using Aegle Marmelos Polysaccharide

Abstract

The purpose of present study was to formulate and evaluate glimepiride gastrobioadhesive drug delivery using Aegle Marmelos polysaccharide and synthetic polymer for prolongation of gastric residence time and reduce the dosing frequency. Glimepiride matrices were prepared by direct compression method and evaluated with an aim of presenting glimepiride as sustained release for improving the patient’s compliance. A central composite design (CCD) was employed as Aegle Marmelos polysaccharide (X1) and HPMC K4M (X2) independent variables to optimize the glimepiride in terms of sustained release and gastrobioadhesive. The response (Y1) as bioadhesive strength, (Y2) percentage drug releases at 8 h and (Y3) time (t50) required to 50% drug release were measured for each trial and statistical equations with significant interaction terms were derived to predict relation. The physical properties of all formulations hardness, friability, drug content and weight variation were found within limits indicating that the prepared matrix tablets met the USP specifications. Among all the formulations, F1 formulation found to be optimized based on the criteria of attaining the maximum value of drug released Q8 of 98.58±1.12%, 18.43 g bioadhesive strength and time to 50% drug release (t50) of 6 h. An in-vitro drug release studies reveals that as concentrations of polymers increases the drug release decreases, producing sustained release of glimepiride. The release co-efficient values ‘n’ (˂0.3645) indicated that the drug release (F1) followed fickian diffusion mechanism kinetics. A glimepiride gastroadhesive matrix was developed to enhance its bioavailability by prolonging the gastric residence time with desirable release modulation for a once daily administration.